Fulcrum Therapeutics (FULC) stock gains as Leerink Partners upgrades the stock, citing a favorable risk-reward setup ahead of a key trial readout. Read more here.

Analysts were effusive about Merus’ new HNSCC data, writing that petosemtamab could “become the standard of care” in the ...

Fintel reports that on May 23, 2025, Leerink Partners upgraded their outlook for Fulcrum Therapeutics (NasdaqGM:FULC) from ...

The advisory committee meeting comes days after the FDA unveiled a new risk-based approval framework for COVID-19 vaccines.

While some analysts questioned why Medtronic would leave a fast-growing market, others backed the company’s plan to focus on ...

Leerink Partners analyst Mani Foroohar reiterated a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price target of $22.00. The company’s shares closed ye ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

A rough earnings report raised troubling questions about UHG’s future, and so did the resignation of CEO Andrew Witty.